NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Iovance Biotherapeutics, Inc. IOVA
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$263.5M
▲ 60.6% vs FY2024
EPS · FY25
$-1.09
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-55.5%
Net margin · FY25
-148.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 263.5M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 148 cents on every revenue dollar this year.
Per share
USD -1.09
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-55.5%
Return on equity, FY2025
ROE
Operating margin-153.1%
Net margin-148.4%
Return on assets-42.9%
Each USD of equity lost 55 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.41B
Shares outstanding, FY2025
Change, 5 years+178.6%
Change, 10 years—
The share count grew 179% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 913.2M
total assets, end of FY2025
Total assetsUSD 913.2M
EquityUSD 698.6M
CashUSD 163.1M
Current ratio3.20×
Equity funds 77% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.3
0.2
0.0
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.4
−0.4
−0.5
−0.4
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.4
−0.4
−0.4
−0.4
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
·
·
·
·
Income tax $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.4
−0.4
−0.4
−0.4
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.09
−1.28
−1.89
−2.49
−2.23
−1.88
−1.59
−1.27
−1.41
−1.85
−0.62
−0.48
−3.47
−4.14
−0.34
−0.02
0.00
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−55.5
−57.5
−81.9
−70.6
−53.6
−54.3
−51.6
−40.4
−58.9
−39.0
−37.2
−38.5
−807.8
·
·
−514.9
·
−2570.8
Shares out B
0.41
0.31
0.26
0.19
0.16
0.15
0.13
0.12
0.07
0.06
0.05
0.03
0.02
0.00
0.08
0.07
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed